Publication:
Rituximab Treatment Is Not Associated with Increased Risk of Infection or Mortality in Refractory SLE Patients: Results from the British Isles Lupus Assessment Group Biologics Registry (BILAG-BR)

Simple item page
dc.contributor.authorsMcDonald, Stephen; McCarthy, Eoghan; Aksoy, Aysun; Parker, Ben; Bruce, Ian
dc.date.accessioned2022-03-10T17:59:49Z
dc.date.accessioned2026-01-11T18:13:56Z
dc.date.available2022-03-10T17:59:49Z
dc.date.issued2019
dc.identifier.doidoiWOS:000507466904285
dc.identifier.eissn2326-5205
dc.identifier.issn2326-5191
dc.identifier.urihttps://hdl.handle.net/11424/222241
dc.identifier.wosWOS:000507466904285
dc.language.isoeng
dc.publisherWILEY
dc.relation.ispartofARTHRITIS & RHEUMATOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.titleRituximab Treatment Is Not Associated with Increased Risk of Infection or Mortality in Refractory SLE Patients: Results from the British Isles Lupus Assessment Group Biologics Registry (BILAG-BR)
dc.typeconferenceObject
dc.type.submeetingabstract
dspace.entity.typePublication
oaire.citation.titleARTHRITIS & RHEUMATOLOGY
oaire.citation.volume71

Files

Collections

Araştırma Çıktıları